New Guidelines Reverse Previous Recommendations on Gluten Introduction to Prevent Celiac Disease
18-Jan-2016 10:50 AM EST
Newswise — January 18, 2016 – Based on new evidence, the age of introduction of gluten into the infant diet—or the practice of introducing gluten during breast-feeding—does not reduce the risk of celiac disease in infants at risk, according to a Position Paper of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). The statement appears in the Journal of Pediatric Gastroenterology and Nutrition (JPGN), official journal of ESPGHAN and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, published by Wolters Kluwer.
Contrary to previous advice, gluten may be introduced anytime between four to twelve completed months of age, the updated recommendations state. Although breastfeeding should be promoted for its other well-established health benefits, current evidence suggests that neither any breastfeeding nor breastfeeding during gluten introduction can reduce the risk of celiac disease.
No Evidence that Timing of Gluten Introduction Affects Celiac Disease RiskCeliac disease is a unique genetic autoimmune disease affecting the gut and other organs, developing in response to consumption of a specific food ingredient—namely gluten. Occurring only in persons carrying one or more susceptibility genes, celiac disease affects approximately one to three percent of the general population in most parts of the world.
In 2008, ESPGHAN issued a recommendation to avoid both early (less than 4 months) and late (7 months or later) introduction of gluten, and to introduce gluten while the infant is still being breastfed. Those recommendations were based on observational studies suggesting that this approach to gluten introduction reduced the risk for celiac disease.
But since then, two randomized controlled trials have shown that the age at gluten introduction does not affect overall rates (incidence and prevalence) of celiac disease during childhood. Earlier gluten introduction causes the disease to present itself at an earlier age. "These findings suggest that primary prevention of celiac disease through nutritional interventions is not possible at the present time," Prof. Szajewska of The Medical University of Warsaw, the lead author of the new Position Paper, comments.
Meanwhile, new observational evidence shows no difference in celiac disease risk when gluten is introduced while the infant is still breast-feeding, compared to after weaning. Because of its many other health benefits, breastfeeding is recommended for all infants, regardless of celiac disease risk.
The updated recommendations are based on studies of infants with known risk genes for celiac disease. However, because this information is generally not known at the time solid foods are introduced, the recommendations apply to all infants.
Celiac disease risk genes are present in 30 to 40 percent of the general European population, as well as in 75 to 80 percent of children who have a close relative (parent or sibling) with celiac disease. For now, there is not enough evidence to make specific recommendations for infants with a family history of celiac disease.
The authors highlight the need for recommendations on screening strategies for children with affected family members. They also call for further studies to determine the best approaches to introducing gluten into the diet—currently, there is no evidence on the effects of delaying gluten introduction for longer than one year.
Article: “Gluten Introduction and The Risk of Coeliac Disease. A Position Paper By The European Society For Paediatric Gastroenterology, Hepatology & Nutrition” (doi: 10.1097/MPG.0000000000001105)
About The Journal of Pediatric Gastroenterology and NutritionThe Journal of Pediatric Gastroenterology and Nutrition provides a forum for original papers and reviews dealing with pediatric gastroenterology and nutrition, including normal and abnormal functions of the alimentary tract and its associated organs, including the salivary glands, pancreas, gallbladder, and liver. Particular emphasis is on development and its relation to infant and childhood nutrition.
About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our products and organization, visit www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.